“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A study looking at ways to predict how well chemotherapy for ovarian cancer will work (CTCR-OV03)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This study used MRI scans and blood and tissue samples to help predict the outcome of chemotherapy for cancer of the ovary. This study was also open to women with ovarian cancer that had spread to the
Doctors usually treat cancer of the ovary with a combination of surgery and chemotherapy. But they cannot always say how well the treatment will work. Doctors don’t want to put people through long courses of treatment and side effects if it won’t help them. If they could develop a test to predict outcome, doctors could work out which treatment will work best for a particular person.
In this study researchers used 3 types of MRI scan, a dynamic enhanced MRI scan (DCE MRI scan), diffusion weighted MRI scan (DW MRI) and magnetic resonance (MR) spectroscopy. They took the scans before and during chemotherapy.
They also collected blood and tissue samples. They looked at the
The aim of this study was to find out if DCE MRI scans could be used to predict how well chemotherapy worked for ovarian cancer.
Summary of results
The study team found that it might be possible to use DCE MRI, DW MRI or MR spectroscopy scans to find out how well chemotherapy would work for ovarian cancer.
This study recruited 28 women. Of these 28 women, 22 had ovarian cancer. Of these 22 women, 20 had a DCE MRI scan, DW MRI scan and MR spectroscopy.
- Before starting their course of chemotherapy
- At least once during their course of chemotherapy
A doctor who specialises in reading scans (
The researchers measured the blood flow to these areas before and during chemotherapy. They looked at the difference in the amount of blood that flowed into these areas of cancer. This was to see if there was link between blood flow before chemotherapy and how well the cancer responded. They found that there was a difference for women whose cancer shrank during treatment.
The study team concluded that these scans may be used to find out in advance how well women with ovarian cancer would respond to treatment.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Evis Sala
Cambridge University Hospitals NHS Foundation Trust
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)